Humoral immunity targeting site I of antigenic domain 2 of glycoprotein B upon immunization with different cytomegalovirus candidate vaccines

Vaccine

Volumn 26, Issue 1, 2007, Pages 41-46

  Axelsson, Fredrika ^a   Adler, Stuart P ^b   Lamarre, Alain ^c   Ohlin, Mats ^a  

^a LUND UNIVERSITY   (Sweden)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c INRS INSTITUT ARMAND FRAPPIER   (Canada)

Author keywords

Live attenuated vaccine; Neutralization epitope; Subunit vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; EPITOPE; GLYCOPROTEIN B; LIVE VACCINE; RECOMBINANT GLYCOPROTEIN B N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE VACCINE; TOWNE VACCINE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CANARYPOX VIRUS; DRUG EFFICACY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN DOMAIN; VACCINATION;

ANTIBODIES, VIRAL; CYTOMEGALOVIRUS VACCINES; EPITOPE MAPPING; HUMANS; IMMUNIZATION; PROTEIN STRUCTURE, TERTIARY; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

EID: 36749092916     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.10.048     Document Type: Article

References (26)

1. Schleiss M. Progress in cytomegalovirus vaccine development. Herpes 12 (2005) 66-75
2. Chatterjee A., Harrison C.J., Britt W.J., and Bewtra C. Modification of maternal and congenital cytomegalovirus infection by anti-glycoprotein B antibody transfer in guinea pigs. J Infect Dis 183 (2001) 1547-1553
3. Fowler K.B., Stagno S., Pass R.F., Britt W.J., Boll T., and Alford C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326 (1992) 663-667
4. Maidji E., McDonagh S., Genbacev O., Tabata T., and Pereira L. Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal Fc receptor-mediated transcytosis. Am J Pathol 168 (2006) 1210-1226
5. Nigro G., Adler S.P., La Torre R., and Best A.M. Congenital Cytomegalovirus Collaborating Group. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353 (2006) 1350-1362
6. Plotkin S. Is there a formula for an effective CMV vaccine?. J Clin Virol 25 (2002) 13-21
7. Snydman D.R., Werner B.G., Meissner H.C., Cheeseman S.H., Schwab J., Bednarek F., et al. Use of cytomegalovirus immunoglobulin in multiply transfused premature neonates. Pediatr Infect Dis J 14 (1995) 34-40
8. Zaia J.A. Prevention and treatment of cytomegalovirus pneumonia in transplant recipients. Clin Infect Dis 7 Suppl. 2 (1993) S392-S399
9. Britt W.J., Vugler L., Butfiloski E.J., and Stephens E.B. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. J Virol 64 (1990) 1079-1085
10. Varnum S.M., Streblow D.N., Monroe M.E., Smith P., Auberry K.J., Pasa-Tolic L., et al. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78 (2004) 10960-10966
11. Spaete R.R., Gehrz R.C., and Landini M.P. Human cytomegalovirus structural proteins. J Gen Virol 75 (1994) 3287-3308
12. Speckner A., Glykofrydes D., Ohlin M., and Mach M. Antigenic domain 1 of human cytomegalovirus glycoprotein B induces a multitude of different antibodies which, when combined, results in incomplete virus neutralization. J Gen Virol 80 (1999) 2183-2191
13. McLean G.R., Olsen O.A., Watt I.N., Rathanaswami P., Leslie K.B., Babcook J.S., et al. Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation to an adaptive immune response. J Immunol 174 (2005) 4768-4778
14. Meyer H., Masuho Y., and Mach M. The gp116 of the gp58/116 complex of human cytomegalovirus represents the amino-terminal part of the precursor molecule and contains a neutralizing epitope. J Gen Virol 71 (1990) 2443-2450
15. Ohlin M., Sundqvist V.-A., Mach M., Wahren B., and Borrebaeck C.A.K. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB) studied by human monoclonal antibodies. J Virol 67 (1993) 703-710
16. Meyer-König U., Haberland M., von Laer D., Haller O., and Hufert F.T. Intragenic variability of human cytomegalovirus glycoprotein B in clinical strains. J Infect Dis 177 (1998) 1162-1169
17. Meyer H., Sundqvist V.A., Pereira L., and Mach M. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies. J Gen Virol 73 (1992) 2375-2383
18. Kropff B., Landini M.P., and Mach M. An ELISA using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus. J Med Virol 39 (1993) 187-195
19. Ohlin M., Silvestri M., Sundqvist V.-A., and Borrebaeck C.A.K. Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques. Clin Diagn Lab Immunol 4 (1997) 107-111
20. Adler S.P., Plotkin S.A., Gönczöl E., Cadoz M., Meric C., Wang J.B., et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180 (1999) 843-846
21. Wang J.B., Adler S.P., Hempfling S., Burke R.L., Duliege A.M., Starr S.E., et al. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 174 (1996) 387-392
22. Ohlin M., Owman H., Mach M., and Borrebaeck C.A.K. Light chain shuffling of a high affinity antibody results in a drift in epitope recognition. Mol Immunol 33 (1996) 47-56
23. Lantto J., Fletcher J.M., and Ohlin M. A divalent antibody format is required for neutralization of human cytomegalovirus via antigenic domain 2 on glycoprotein B. J Gen Virol 83 (2002) 2001-2005
24. Spaete R.R. A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 23 (1991) 90-96
25. Lantto J., Fletcher J.M., and Ohlin M. Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein B of human cytomegalovirus. Virology 305 (2003) 201-209
26. Masuho Y., Matsumoto Y.I., Sugano T., Fujinaga S., and Minamishima Y. Human monoclonal antibodies neutralizing human cytomegalovirus. J Gen Virol 68 (1987) 1457-1461